Genmab A/S
Denmark · DK0010272202 · reports in USD · Europe
Four figures
From the annual report for the year to Dec 31, 2025. Each line says what it is based on.
- Revenue growth
- Revenue +19% in the year to Dec 31, 2025, on the year before.
- Return on equity
- It earned 16% on its shareholders' equity in the year to Dec 31, 2025.
- Equity and assets
- Equity is 45% of its assets, and operations brought in cash in the year.
- Price and earnings
- Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.
The year
Year to Dec 31, 2025, consolidated, in USD.
$3.7B
revenue
29%
operating margin
$963M
net profit
Year by year
As filed; an earlier year can differ from its own report when the company restated it.
| Dec 2023 | Dec 2024 | Dec 2025 | |
|---|---|---|---|
| Revenue | $2.4B | $3.1B | $3.7B |
| Operating profit | $772M | $972M | $1.1B |
| Earnings per share | $9.67 | $17.66 | $15.50 |
| Cash from operations | $1.1B | $1.1B | $1.2B |
| Capital spending | $53M | $27M | $37M |
| Cash | $2.2B | $1.4B | $1.7B |
| Total assets | $5.2B | $6.4B | $12.9B |
| Equity | $4.7B | $5.1B | $5.8B |
Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the ratios from the filed figures.